Galecto Biotech

The company develops disease-modifying subcutaneous biologics for patients with mutant calreticulin-driven myeloproliferative neoplasms, such as Essential Thrombocythemia and Myelofibrosis. Its lead candidate, DMR-001, is a monoclonal antibody designed to selectively bind to mutant calreticulin to inhibit cell proliferation. The firm targets approximately 42,000 patients in the U.S. who currently lack treatments addressing the underlying cause of these rare blood disorders.